On Friday shares of Aramark (NYSE:ARMK) closed at $32.55. Company’s EPS growth for next 5 years is recorded as 11.60%. Aramark (NYSE:ARMK) announced that certain of its stockholders, consisting of affiliates of GS Capital Partners, CCMP Capital Advisors, LLC, J.P. Morgan Partners, LLC, Thomas H. Lee Partners, L.P. and Warburg Pincus LLC, intend to offer for sale in an underwritten secondary offering 22,500,000 shares of its common stock pursuant to Aramark’s shelf registration statement filed with the Securities and Exchange Commission (the “SEC”).
Amicus Therapeutics, Inc. (NASDAQ:FOLD) in last trading activity moved down -6.82% to close at $11.61. Company weekly performance is 25.51% while its quarterly performance stands at 48.28%. Amicus Therapeutics Inc (NASDAQ:FOLD) announced Thursday morning that it accelerated its submission timeline for its marketing authorization application for migalastat monotherapy in the European Union to the second quarter of 2015. After a meeting with the FDA, the company also plans to submit a new drug application for accelerated approval in the second half of 2015.
On last trading day TTM Technologies Inc. (NASDAQ:TTMI) moved down -0.66% to close at $9.05. Its volatility for the week is 2.61% while volatility for the month is 2.59%. TTMI’s sales growth for past 5 years was 17.90% and its EPS growth for past 5 years was 10.40%. TTM Technologies Inc. (NASDAQ:TTMI) monthly performance is -0.66%.
On Friday shares of International Business Machines Corporation (NYSE:IBM) closed at $162.88. Company’s sales growth for last 5 years was -0.60% and EPS growth for next 5 years is recorded as 4.51%. International Business Machines Corporation (NYSE:IBM) in 2013 began offering its technology for other companies for use in their own chips and computers. Now some tech firms in China are taking Big Blue up on it.
On last trading day Kite Pharma, Inc. (NASDAQ:KITE) moved down -2.20% to close at $71.89. Its volatility for the week is 8.31% while volatility for the month is 6.15%. Kite Pharma, Inc. (NASDAQ:KITE) monthly performance is 12.50%. On Mar 17, 2015. announced that it has further strengthened its TCR product platform and established a European presence through the acquisition of T-Cell Factory B.V. (TCF™), a privately held Dutch company, which has been renamed Kite Pharma EU. Founded by preeminent scientists, including Professor Dr. Ton N. M. Schumacher, Ph.D., of the Netherlands Cancer Institute (NKI) and Professor Dr. Dirk H. Busch, M.D., of the Technische Universität München (TUM).